LIGAND PHARMACEUTICALS INCORPORATED
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $341.3M | $18.8M |
| FY2017 | — | $399.8M | $20.6M |
| FY2018 | — | $560.9M | $117.2M |
| FY2019 | — | $767.2M | $71.5M |
| FY2020 | — | $709.5M | $47.6M |
| FY2021 | — | $821.2M | $19.5M |
| FY2022 | — | $597.5M | $45.0M |
| FY2023 | — | $700.9M | $23.0M |
| FY2024 | — | $830.4M | $72.3M |
| FY2025 | — | $1.02B | $174.9M |